Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he plans to take to ensure that the roll-out of the covid-19 vaccine does not have a negative effect on clinical trials for other diseases.

The Medicines and Healthcare products Regulatory Agency (MHRA) has provided advice to clinical trial sponsors to conduct a specific risk assessment for concomitant use of a COVID-19 vaccine in their trial, taking into consideration each investigational medicinal product used in the trial and with specific consideration for the trial population. If a trial needs to be amended to facilitate continuation, then the MHRA will consider any application and advise as necessary.